Citable filing context

MDT filing events and research context

Server-rendered

MDT's research view summarizes recent SEC filing context, starting with management_change from May 18, 2026.

MDT filing events and research context
FiledItemContext
May 18, 2026management_changeBrett Wall departed as EVP and President, Neuroscience Portfolio; Dr. Kweli Thompson appointed to the role.
Apr 27, 2026otherMedtronic announced unauthorized data access in its IT systems on April 24, 2026.
Mar 24, 2026guidance_updateMedtronic revised FY2026 non-GAAP EPS guidance from $5.62-$5.66 to $5.50-$5.54.
Mar 24, 2026Guidance: eps_growthnot reported to not reported
Mar 24, 2026Guidance: non_gaap_eps5.50 to 5.54
Feb 17, 2026Guidance: diluted_non_gaap_eps5.62 to 5.66
Feb 24, 2026mda_quarterlyMedtronic reported a 9% increase in net sales to $9.02 billion for the three months ended January 23, 2026, driven by broad-based growth and favorable foreign currency impacts. GAAP diluted EPS decreased to $0.89 from $1.01, while Non-GAAP diluted EPS saw a slight decline to $1.36 from $1.39. Operating cash flow for the nine months rose to $4.76 billion, yielding $3.34 billion in free cash flow. Cardiovascular sales grew 14%, propelled by strong performance in Cardiac Rhythm & Heart Failure, notably Micra leadless pacemakers, Aurora EV-ICD, and pulsed field ablation. Diabetes sales surged 15%, primarily from international adoption of the MiniMed 780G AID system and Simplera Sync CGM, ahead of its planned separation within 18 months. Neuroscience and Medical Surgical segments also contributed to growth, increasing 4% and 5% respectively, with key products like the AiBLE ecosystem and LigaSure vessel sealing technology performing well. Cost of products sold increased due to $90 million in tariffs and asset write-offs, while SG&A expenses rose from sales growth, new product launches, and costs related to the Diabetes separation. The effective tax rate increased to 18.1% due to the Pillar Two global minimum tax. Macroeconomic risks include an estimated $185 million pre-tax tariff impact in fiscal year 2026, competitive pressures, and supply chain challenges. The company maintains a strong liquidity position with $1.1 billion in cash and $7.2 billion in current investments, and total debt decreased to $28.1 billion.
Nov 25, 2025mda_quarterlyMedtronic reported a 7% increase in net sales to $8.96 billion and a 7% rise in Non-GAAP diluted EPS to $1.36 for the three months ended October 24, 2025. Cardiovascular sales grew 11%, propelled by Cardiac Ablation Solutions (PulseSelect, Affera Sphere-9), TAVR (Evolut FX+), and Cardiac Pacing Therapies (Micra, Aurora EV-ICD). Neuroscience sales increased 5%, led by Neuromodulation (Inceptiv, Percept RC) and Cranial & Spinal Technologies, despite a Neurovascular Pipeline Vantage recall and China tender pricing. Diabetes sales surged 10% internationally, driven by the MiniMed 780G AID system. Key product developments include the Evolut FX+ TAVR system, Symplicity Spyral renal denervation (with CMS coverage), and the Inceptiv closed-loop spinal cord stimulator. The company is preparing for the impending separation of its Diabetes business. Macroeconomic risks include an estimated $185 million pre-tax tariff impact in fiscal year 2026, competitive pressures, and supply chain challenges. Liquidity remains strong with $1.3 billion cash and $7.0 billion current investments. Total debt increased to $29.1 billion, reflecting increased commercial paper and foreign exchange impacts, partially offset by Euro-denominated debt repayments. Medtronic repurchased 5 million shares, with $1.7 billion remaining under authorization. The effective tax rate decreased to 13.5% due to a tax benefit from uncertain tax positions, partially offset by Pillar Two global minimum tax impacts.

Source: SEC EDGAR filing text and events; period May 18, 2026; filed May 18, 2026.

Continue research

Keep researching MDT

Follow same-sector companies and source explainers connected to the research view.

Browse Health Care

Related tickers

LLY
Lilly (Eli)
$1.02T
Health Care
Open company page →
JNJ
Johnson & Johnson
$558.88B
Health Care
Open company page →
ABBV
AbbVie
$393.91B
Health Care
Open company page →
UNH
UnitedHealth Group
$369.32B
Health Care
Open company page →
MRK
Merck & Co.
$295.00B
Health Care
Open company page →
AZN
ASTRAZENECA PLC
$281.75B
Health Care
Open company page →

Related explainers

Understanding 8-K filings

A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.

Read explainer →
Reading a 10-Q

A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.

Read explainer →
S-1 and the IPO prospectus

A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.

Read explainer →
Reading an SEC 10-K

A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.

Read explainer →